Submitted by Luciana Ferreira (lucgeral@gmail.com) on 2014-09-23T13:40:05Z
No. of bitstreams: 2
Sousa, Eduardo Martins.pdf: 2216793 bytes, checksum: b28a546dbb9489fa820abe22bc2b6109 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2014-09-23T15:17:05Z (GMT) No. of bitstreams: 2
Sousa, Eduardo Martins.pdf: 2216793 bytes, checksum: b28a546dbb9489fa820abe22bc2b6109 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2014-09-23T15:17:05Z (GMT). No. of bitstreams: 2
Sousa, Eduardo Martins.pdf: 2216793 bytes, checksum: b28a546dbb9489fa820abe22bc2b6109 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Previous issue date: 2013-03-27 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / Tuberculosis is a re-emerging infectious disease that remains a major public health problem worldwide. Although there is the BCG vaccine that is effective against severe forms of childhood TB, in adults its efficacy is variable (0-85%). In this context there is a need to develop new vaccines to control the spread of TB. This thesis proposes the development of a new recombinant fusion M. tuberculosis protein (Ag85C-MPT51-HspX) by molecular cloning, expression in E. coli with a histidine tag and purified by ion exchange chromatography. The fusion protein was constructed successfully, expressed in E. coli BL21 and purified. Tests in mice were performed to evaluate the immunogenicity of the recombinant fusion protein Ag85C-MPT51-HspX of M. tuberculosis. Mice were immunized three times with the protein Ag85C-MPT51-HspX formulated with CpG-DNA encapsulated in liposomes, CpG-DNA encapsulated in liposomes, liposome or saline as negative control and the humoral and cellular immune response was evaluated. The immunization with the vaccine formulation induced the production of high titers of specific anti-fusion protein Ag85C-MPT51-HspX IgG1 = 3.08 ± 0.04; IgG2a = 3.10 ± 0.03) and, favored the increase of specific CD4+ IFN-γ (2.14% ± 0.17), CD4+ TNF-α (2.16 ± 0.34%). The recognizing of this protein by seric IgG and IgM discriminated patients with active TB infection from healthy individuals. We conclude that CMX protein has potential to be used for the development of vaccine against M. tuberculosis as well also for TB diagnostic kits. / A tuberculose é uma doença infecciosa re-emergente que permanece como um dos maiores problemas de saúde pública mundial. Embora exista a vacina BCG que é eficiente contra formas graves de TB na infância, em adultos a eficácia é variável (0 a 85%). Nesse contexto existe a necessidade do desenvolvimento de novas vacinas para controlar a disseminação da TB. O presente trabalho teve como objetivo desenvolver uma nova proteína de fusão recombinante (Ag85C-MPT51-HspX) de M. tuberculosis a partir da clonagem molecular, expressão em E. coli com uma cauda de histidina e purificação através de cromatografia de troca iônica. A proteína de fusão foi construída com sucesso expressa em E. coli BL21 e purificada. Ensaios em camundongos foram realizados para avaliar a imunogenicidade da proteína recombinante de fusão Ag85C-MPT51-HspX de M. tuberculosis. Os camundongos foram imunizados três vezes com a proteína Ag85C-MPT51-HspX formulada com CpG-DNA encapsulada em lipossoma, CpG-DNA encapsulado em lipossoma, lipossoma ou salina como controle negativo e a resposta imune humoral e celular foi avaliada . A imunização com a formulação vacinal induziu a produção de altos títulos de anticorpos específicos anti-proteína de fusão Ag85C-MPT51-HspX (IgG1 =3,08±0,04; IgG2a=3,10±0,03), bem como, favoreceu o aumento de células T CD4+IFN-γ (2,14%±0,17), CD4+TNF-α (2,16%±0,34) específicas. A avaliação do reconhecimento desta proteína de fusão tanto por IgM quanto IgG humana sérica permitiu discriminar pacientes com tuberculose ativa de controles saudáveis, demonstrando a antigenicidade desta molécula em humanos. Conclui-se que a proteína CMX poderá ser testada tanto como vacina, assim como para o desenvolvimento de testes de diagnóstico para a tuberculose.
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.bc.ufg.br:tede/3130 |
| Date | 27 March 2013 |
| Creators | Sousa, Eduardo Martins de |
| Contributors | Junqueira-Kipnis, Ana Paula, Araújo Filho, João Alves de, Kipnis, André, Junqueira-Kipnis, Ana Paula, André, Maria Cláudia Dantas Porfírio Borges, Bocca, Anamelia Lorenzentti, Palaci, Moisés, Fonseca, Simone Gonçalves da |
| Publisher | Universidade Federal de Goiás, Programa de Pós-graduação em Medicina Tropical e Saúde Publica (IPTSP), UFG, Brasil, Instituto de Patologia Tropical e Saúde Pública - IPTSP (RG) |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/doctoralThesis |
| Format | application/pdf |
| Source | reponame:Biblioteca Digital de Teses e Dissertações da UFG, instname:Universidade Federal de Goiás, instacron:UFG |
| Rights | http://creativecommons.org/licenses/by-nc-nd/4.0/, info:eu-repo/semantics/openAccess |
| Relation | 6085308344741430434, 600, 600, 600, 600, -7769011444564556288, -317746863433440698, -2555911436985713659, 1. ABOU-ZEID C, ROOK G, MINNIKIN DE, PARLETT JH, OSBORN TW & GRANGE JM. 1987. Effect of the method of preparation of bacillus Calmette-Guérin (BCG) vaccine on the properties of four daughter strains. Journal of Applied Bacteriology. 63: 449-453. 2. ACHKAR JM, DONG Y, HOLZMAN RS, BELISLE J, KOURBETI IS, SHERPA T, CONDOS R, ROM WN AND LAAL S. 2006. Mycobacterium tuberculosis Malate Synthase- and MPT51-Based Serodiagnostic Assay as an Adjunct to Rapid Identification of Pulmonary Tuberculosis. Clin Vaccine Immunol. 13(11): 1291–1293. 3. ACHKAR JM, JENNY-AVITAL E, YU X, BURGER S, LEIBERT E, BILDER PW, ALMO SC, CASADEVAL AL, LAAL S. 2010. Antibodies against Immunodominant Antigens of Mycobacterium tuberculosis in Subjects with Suspected Tuberculosis in the United States Compared by HIV Status. Clin Vaccine Immunol. 17(3): 384–392. 4. ADAMS DO. 1976. The granulomatous inflammatory response. A review. Am. J.Pathol. 84:164-191. 5. ADEREM A, UNDERHILL DM. 2002. Mechanisms of phagocytosis in macrophages. Annu Review Immunology; 17: 593-623. 1999. 6. ALMEIDA CMC, VASCONCELOS-JR AC, KIPNIS A, ANDRADE AL, JUNQUEIRA-KIPNIS AP. 2008. Humoral Immune Responses of Tuberculosis Patients in Brazil Indicate Recognition of Mycobacterium tuberculosis MPT-51 and GlcB. Clin Vaccine Immunol;3: 579-581. 7. ANDERSEN P. 2007. Vaccine strategies against latent tuberculosis infection. Trends Microbiol, 15, pp. 7–13. 8. ARAÚJO-FILHO JA, VASCONCELOS AC Jr, SOUSA EM, KIPNIS A, RIBEIRO E, JUNQUEIRA-KIPNIS AP. 2008. Cellular responses to MPT-51, GlcB and ESAT-6 among MDR-TB and active tuberculosis patients in Brazil. Tuberculosis;88(5):474-81. 9. BEHR MA, WILSON MA, GILL WP, SALAMON H, SCHOOLNIK GK, RANE S, SMALL PM. 1999. COMPARATIVE GENOMICS OF BCG VACCINES BY WHOLE-GENOME DNA MICROARRAY. SCIENCE. 5419: 1520-3. 10. BELISLE JT, VISSA VD, SIEVERT T, TAKAYAMA K, BRENNAN PJ, BESRA GS. 1997. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science, 276, pp. 1420–1422. 11. BENENSON A 1997. Manual para el control de las enfermedades transmisibles. Organización Panamericana de la Salud.16a ed., Washington. 12. BILLESKOV R, ELVANG TT, ANDERSEN PL, DIETRICH J. 2012. The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity. Plos One. 7(6): e39909. 13. BLACK GF, WEIR RE, FLOYD S, BLISS L, WARNDORFF DK, CRAMPIN AC, et al. 2002. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet. 359:1393-401. 14. BLOOM BR & FINE PEM. 1994. The BCG experience: implications for future vaccine against tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection and control. Washington: American Society of Microbiology; p. 531-57. 15. BLOOM BR & JACOBS WR Jr.1999. New strategies for leprosis and tuberculosis and for development of bacillus Calmette-Guerin into a multivaccine vechicle. Ann. N. Y. Acad. Sci; 569: 155-73. 16. BOEHM U, KLAMP T, GROOT M, HOWARD JC. 1997. Cellular response to interferon-, Annu Review Immunology; 15:749-795. 17. BOOM WH, CANADAY DH, FULTON SA, GEHRING AJ, ROJAS RE, TORRES M. 2003. Human immunity to Mycobacterium tuberculosis: T cell subsets and antigen processing. Tuberculosis, 86:98-106. 18. BOSHOFF, HI, and CE. BARRY III. 2005. Tuberculosis: metabolism and respiration in the absence of growth. Nat. Rev. Microbiol. 3:70-80. 19. BRANDT L, SKEIKY YAW, ALDERSON MR, LOBET Y, DALEMANS W, TURNER OC, BASARABA RJ, IZZO AA, LASCO TM, CHAPMAN PL, REED SG ; ORME IM. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect immun 72: 6622-6632. 20. BRENNAN PJ, NIKAIDO H 1995. The envelope of mycobacteria. Annu Review Biochemical 64: 29-63. 21. BREWER JM. 2006. (How) do aluminium adjuvants work? Immunology letters,102(1):10-5. 22. BRUYN G & GARNER P. 2003. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev. 1:CD001166. 23. BURDIN N, GUY B, MOINGEON P. 2004. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs. 18(2):79-93. 24. CAMUS JEAN-CHRISTOPHE, MELINDA J. PRYOR, CLAUDINE MDIGUE, STEWART T. COLE. 2002 Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology. 2002; 148: 2967 - 2973. 25. CONSTANT P, DAVODEAU F, PEYRAT MA, POQUET Y, PUZO G, BONNEVILLE M, FOURNIE JJ. 1994. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science, Vol 264, 267-270. 26. COOPER AM, KHADER SA. 2008. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunological Rev. 226:191-204. 27. COUSINS DV, BASTIDA R, CATALDI A, OUSE V, REDROBE S, DOW S, DUIGNAN P, MURRAY A, DUPONT C, AHMED N, COLLINS DM, BUTLER WR, DAWSON D, RODRIGUEZ D, LOUREIRO J, ROMANO MI, ALITO A, ZUMARRAGA M & BERNARDELLI A. 2003. Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov. International Journal of Systematic and Evolutionary Microbiology. 53: 1305-14. 28. CRUZ A, FRAGA AG, FOUNTAIN JJ, RANGEL-MORENO J, TORRADO E, SARAIVA M, PEREIRA DR, RANDALL TD, PEDROSA J, COOPER AM, CASTRO AG. 2010. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med. 2; 207 (8):1609-16. 29. CRUZ A, KHADER SA, TORRADO E, FRAGA A, PEARL JE, PEDROSA J, COOPER AM & CASTRO AG. 2006. IFN- regulates the induction and expasion of IL-17-producing CD4 T cells during Mycobacterial Infection. Journal of Immunology, 177:1416-20. 30. D’SOUZA S, ROSSEELS V, DENIS O, TANGHE A, DE SMET N, JURION F, PALFLIET K, CASTIGLIONI N, VANONCKELEN A, WHEELER C, HUYGEN K. 2002. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infection Immunology. 70(7):3681-8. 31. DAFFE M, DRAPER P. 1998. The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microbiology Physiology; 39:131-203. 32. DANNENBERG AM. 1993. Immunopathogenesis of pulmonary tuberculosis. Hosp. Pract. 28: 51-58. 33. DE GREGORIO E, TRITTO E, RAPPUOLI R. 2008. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 38: 2068-2071. 34. DEMISSIE A, LEYTEN EM, ABEBEM, WASSIE L, ASEFFA A, ABATE G, FLETCHER H, OWIAFE P, HILL PC, BROOKES R, ROOK G, ZUMLA A, AREND SM, KLEIN M, OTTENHOFF TH, ANDERSEN P and DOHERTY TM. 2006. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 13:179-186. 35. DEY B, JAIN R, FUPTA UD, KATOCH VM, RAMANATHAN VD, TYAGI AK. 2011. A Booster Vaccine Expressing a Latency-Associated Antigen Augments BCG Induced Immunity and Confers Enhanced Protection against Tuberculosis. PLoS One 6: e23360. 36. DIELI F, TROYE-BLOMBERG M, IVANYI J, FOURNIÉ JJ, BONNEVILLE M, PEYRAT MA, SIRECI G, SALEMO A 2000. V9/V2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur J Immunology; 30: 1512-1519. 37. DIETRICH J, AAGAARD C, LEAH R, OLSEN AW, STRYHN A, DOHERTY TM et al. 2005. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol, 174, pp. 6332–6339. 38. DINIZ DGA, RIBAS PT, OLIVEIRA FS, VALADARES MC, LIMA EM. 2007. Avaliação da atividade antitumoral da isotretinoína encapsulada em lipossomas e nanocápsulas de PLA e PLGA. Rev Eletrônica de Farmácia, (2),23-25, 2007 39. DOHERTY TM, ARDITE M. 2004. TB, or not TB: that is the question – does TLR signaling hold the answer? Journal Clinical Invest.; 12:1699-1703. 40. DUPUIS S, DOFFINGER R, PICAR C, FIESCHI C, ALTARE F, JOUANGUY E, ABEL L, CASANOVA LJ 2000. Human interferon- mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion Immunology Review; 178:129-137. 41. ERNEST JD. 1998. Macrophages receptor for Mycobacterium tuberculosis. Infection Immunology; 66: 12377-12381. 42. ESPINAL MA. 2003. The global situation of MDR-TB. Tuberculosis (Edinb) 83: 44-51. 43. FERREIRA AP, AGUIAR AS, FAVA MW, CORRÊA JO, TEIXEIRA FM, TEIXEIRA HC. 2002. Can the efficacy of bacille calmette-guerin tuberculosis vaccine be affected by intestinal parasitic infections? J Infect Dis. 186:441-2. 44. FINE PE. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet, 346, pp. 1339–1345. 45. FLYNN JL, CHAN J. 2001. Inmunology of tuberculosis. Annu Review Immunology; 19: 93-129. 46. FLYNN JL, CHAN J. 2005. What's good for the host is good for the bug. Trends Microbiol. 13: 98-102. 47. FREGUSON JS, SCHELESINGER LS. 2000. Pulmonary surfactant in innate immunity and pathogenesis of tuberculosis. Tubercle and Lung Disease; 80:173-184. 48. FREUND J, CASALS J, HOSMER E. 1937. Sensitization and antibody formation after injectin of tubercle bacilli and parafin oil. Proc Soc Exp Biol Med. 37:509-13. 49. GARCÍA MA, BORRERO R, MARRÓN R, LANJJO ME, CANET L, OTERO O, KADIR R, SURAIYA S, ZAYAS C, LÓPEZ Y, NORAZMI MN, SARMIENTO ME, ACOSTA A. 2013. Evaluation of specific humoral immune response and cross reactivity againstMycobacterium tuberculosis antigens induced in mice immunized with liposomes composed of total lipids extracted from Mycobacterium smegmatis. BMC Immunol. 14(Suppl 1):S11. 50. GARCON N, CHOMEZ P, VAN MECHELEN M. 2007. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines, 6(5):723-39. 51. GELUK A, LIN MY, VAN MEIJGAARDEN KE, LEYTEN EMS, FRANKEN KLMC, OTTENHOFF THM, and KLEIN MR. 2007. T-Cell Recognition of the HspX Protein of Mycobacterium tuberculosis Correlates with Latent M. tuberculosis Infection but Not with M. bovis BCG Vaccination. Infect Immun. 75: 2914-2921. 52. GLENNY A, POPE C, WADDINGTON H, WALLACE V. 1926. The antigenic value of toxoid precipitated by potassium-alum. J Path Bacteriol.29:38-45. 53. GONG JH, ZHANG M, MODLIN RL, LINSLEY PS, LYER D, LIN Y, BARNES PF. 1996. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect Immun;64(3):913-8. 54. GRANGE JM, GIBSON JA, OSBORN TW, COLLINS CH, YATES MD. 1993. What is BCG?. Tubercle; 64:129-39. 55. GREGORIADIS G, GURSEL I, McCORMACK B. 1996. Liposomes as immunological adjuvants and vaccine carriers. J of Controlled Release 41:49-56. 56. GRODE P, SEILER P, BAUMANN S, HESS J, BRINKMANN V, NASSER EDDINE A. et al. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin J Clin Invest, 115, pp. 2472–2479. 57. GURUNATHAN S, KLINMAN DMK, SEDER RA. 2000. DNA Vaccines: Immunology, Application, and Optimization. Annu. Rev. Immunol, 18, p. 927 58. HARTH, G, LEE, BY, WANG, J, CLEMENS, DL, HORWITZ, MA. 1997. Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis. Infect. Immun. 65, 852. 59. HAWGOOD BJ (2007) Albert Calmette (1863-1933) and Camille Guerin (1872-1961): the C and G of BCG vaccine J. Med. Biogr, 15 pp. 139–146. 60. HEMMI H, TAKEUCHI O, KAWAI T, KAISHO T, SATO S, SANJO H, MATSUMOTO M, HOSHINO K, WAGNER H, AKIRA S. 2000. A Toll-like receptor recognizes bacterial DNA. Nature,7;408(6813):740-5. 61. HESS J, MIKO D, CATIC A, LEHMENSIEK V, RUSSEL DG, KAUFMANN SHE. 1998. Mycobacterium bovis bacilli Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. 95:5299-5304. 62. HINGLEY-WILSON SM. 2000. The immunobiology of the mycobacterial infected macrophage. Mod. Asp. Immunobiol.1: 96-101. 63. HORWITZ MA, HARTH G, DILLON BJ, MASLESA-GALIC S. 2000. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc.Natl. Acad. Sci. 97:13853-58. 64. HORWITZ, MA, BW LEE, BJ DILLON, and G. HARTH. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 92: 1530–1534. 65. HUEBNER RE. 1994. BCG Vaccination the Control of Tuberculosis in: Tuberculosis. Edited by Barry Bloom. American Society for Microbiology, Chapter; 23:263- 279. 66. HUYGEN K. 1998. DNA vaccines: application to tuberculosis. Int Journal Tuberculoses Lung Disease; 2(12): 971-78. 67. JANEWAY CA Jr., MEDZHITOV R. 2002. Innate immune recognition. Annu Rev Immunol. 20:197-216. 68. JOHANSEN P, RAYNAUD C, YANG M, COLSTON MJ, TASCON RE, LOWRIE DB. 2003. Anti-mycobacterial immunity induced by a single injection of M. leprae Hsp65-encoding plasmid DNA in biodegradable microparticles.Immunol Lett. 90:81-5. 69. KAUFMANN SHE & NASSER A. 2005. Improved protection by recombinant BCG. Microbes and Infection. 7: 939-946. 70. KAUFMANN SHE. 2004. New issues in tuberculosis. Ann Rheum Disease; 63:50-56. 71. KAUFMANN SHE. 2005. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26:660-7. 72. KHAN IH, RAVINDRAN R, YEE J, ZIMAN M, LEWINSOHN DM, GENNARO ML, FLYNN JL, GOULDING CW, DERIEMER K, LERCHE NW, LUCIW PA. 2008. Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis. Clin Vaccine Immunol;15(3):433-8. 73. KHERA A, R. SHAKILA SH, RAO V, DHAR N, NARAYANAN PR, PARMASIVAN CN, RAMANATHAN VD, TYAGI AK. 2005. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine, 23, 5655–5665. 74. KILBURN JO, TAKAYAMA K, ARMSTRONG EL. 1982. Synthesis of trehalose dimycolate (cord factor) by a cell-free system of Mycobacterium smegmatis. Biochem. Biophys. Res. Commun. 108, 132–139. 75. KITAURA H, OHARA N, NAITO M, KOBAYASHI K, YAMADA T. 2000. Fibronectin-binding proteins secreted by Mycobacterium avium. APMIS. 108:558-64. 76. LAUNOIS P, DELEYS R, NIANG MN, DROWART A, ANDRIEN M, DIERCKX P, CARTEL JL, SARTHOU JL, VAN VOOREN JP, HUYGEN K. 1994. T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infec. Immun., 62, pp. 3679–3687. 77. LEROUX-ROELS G. 2010. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine. 31;28 Suppl 3:C25-36 78. LEYTEN EM, LIN MY, FRANKEN KL, FRIGGEN AH, PRINS C, VAN MEIJGAARDEN KE, VOSKUIL MI, WELDINGH K, ANDERSEN P, SCHOOLNIK GK, AREND SM, OTTENHOFF TH, and KLEIN MR. 2006. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 8:2052-2060. 79. LI. B, BASSIRI H, ROSLSMAN MD, KRAMER P, ONER EYUBOGLU F, TORRES M, SADA E, IMIR T, CARDING SR 1998. Involvement of the Fas/Fas Ligand pathway in activation-induced cell death of Mycobacteria-reactive human T cells: A mechanism for the loss of T cell in patients with pulmonary tuberculosis. Journal Immunology; 161:1558-1567. 80. LI H, WILLINGHAM SB, TING JP, RE F. 2008. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated byNLRP3.J Immunol. 181(1):17-21. 81. LIN Y, ZHANG M, HOFMAN FM, GONG J, BARNES PF 1996. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immunology; 64:1351-1356. 82. LOWRIE DB & SILVA CL. 2000. Enhancement of immunocompetence in tuberculosis by DNA vaccination. Vaccine. 18:1712-6. 83. LOWRIE DB, TASCO RE, COLSTON MJ, SIILVA CL. 1994. Towards a DNA vaccine against tuberculosis. Vaccine;12(16):1537-40. Review. 84. LOWRIE DB, TASCON RE, BONATO VL, LIMA VM, FACCIOLI LH, STAVROPOULOS E, COLSTON MJ, HEWINSON RG, MOELLING K, SILVA CL. 1999. Therapy of tuberculosis in mice by DNA vaccination. Nature 15;400(6741):269-71. 85. LOWRIE DB. 2003. DNA vaccination: an update. Methods Mol Med. 87:377-90. 86. MAGALHAES I, SIZEMORE DR, AHMED RK, MUELLER S, WEHLIN L, SCANGA C et al. 2008.. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One, 3 (2008), p. e3790. 87. MARTIN C, 2005. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Europe Respir Journal; 26(1):162-7. 88. MARTIN C, WILLIAMS A, HERNANDEZ-PANDO R, CARDONA PJ, GORMLEY E, BORDAT Y. et al. 2006. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine, 24, pp. 3408–3419. 89. MCNEIL M, DAFFE M AND BRENNAN PJ 1990. Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cells walls. Journal Biol Chem; 265:18200-18206. 90. MCSHANE H, BROOKES R, GILBERT SC AND HILL AV 2001. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immunology; 69: 681-86. 91. MCSHANE H, PATHAN AA, SANDER CR, KEATING SM, GILBERT SC, HUYGEN K 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boost BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat med; 10(11): 1240-44. 92. MEACCI F, ORRU G, IONA E, GIANNONI F, PIERSIMONI C, POZZI G, FATTORINI L, OFFIONI MR. 2005. Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol 43: 3114-3120. 93. MIKUSOVA K, YAGI T, STERN R, MCNEIL MR, BESRA GS, CRICK DC AND BRENNAN PJ 2000. Biosynthesis of the galactan component of the mycobacterial cell wall. Journal Biol Chem; 275: 33890-33897. 94. MOLLENKOPF HJ, GROINE-TRIEBKORN D, ANDERSEN P, HESS J AND KAUFMANN SH 2001. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine; 19(28-29): 4028-35. 95. MUELLER H, FAÉ KC, MAGDORF K, GANOZA CA, WAHN U, GUHLICH U, FEITERNA-SPERLING C, KAUFMANN SH. 2011. Granulysin-expressing CD4+ T cells as candidate immune marker for tuberculosis during childhood and adolescence. PLoS One; 6(12):e29367. 96. NAGAI P, MCCORMICK S, SMALL C, ZHANG X, ZGANIACZ A, AOKI N, XING Z. 2007. Gamma interferon responses of CD4 and CD8 T-cell subsets are quantitatively different and independent of each other during pulmonary Mycobacterium bovis BCG infection. Infect Immunology.75: 2244-52. 97. NAGAI S, WIKER HG, HARBOE M AND KINOMOTO M 1991. Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infection Immunology; 59: 372-382. 98. NEWPORT MJ, HUXLEY CM, HUSTON S, HAWRYLOWICZ CM, OOSTRA BA, WILLIAMSON R.; LEVIN, M. 1996. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl Journal Med 335:1941–1949. 99. NUNN P, WILLIAMS B, FLOYD K, DYE C, ELZINGA G, RAVIGLIONE M. 2005 .Tuberculosis control in the era of HIV. Nat Rev Immunol 5: 819-826. 100. O'HAGAN DT, RAPPUOLI R. 2004. Novel approaches to vaccine delivery. Pharm Res. 21(9):1519-30. 101. OHARA N, NISHIYAMA T, OHARA-WADA N, MATSUMOTO S, MATSUO T AND YAMADA T. 1997a. Characterization of the transcriptional initiation regions of genes for the major secreted protein antigens 85 C and MPB51 of Mycobacterium bovis BCG. Microbiology Pathog; 23: 303-310 (a). 102. OHARA N, OHARA-WADA N, KITAURA H, NISHIYAMA T, MATSUMOTO S AND YAMADA T 1997b. Analysis of the genes encoding the antigen 85 complex and MPT51 from Mycobacterium avium. Infection Immunology; 65: 3680-3685 (b). 103. OKKELS LM, DOHERTY TM & ANDERSEN P. 2003. Selecting the components for a safe and efficient tuberculosis subunit vaccine – recent progress and post-genomic insights. Curr. Pharm. Biotechnol. 4, 69-83. 104. ORDWAY DJ, COSTA L, MARTINS M, SILVEIRA H, AMARAL L, ARROZ MJ, VENTURA FA, DOCKRELL HM. 2004. Increased Interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infection Disease. 15;190(4):756-66. 105. ORDWAY DJ, PINTO L, COSTA L, MARTINS M, LEANDRO C, VIVEIROS M, AMARAL L, ARROZ MJ, VENTURA FA, DOCKRELL HM. 2005. Gamma delta T cell responses associated with the development of tuberculosis in health care workers. FEMS Immunology Medical Microbiology, 1;43(3):339-50. 106. ORME I 2004. Adaptative immunity to mycobacteria. Curr Op Microbiol; 7:58-61. 107. ORME IA, COOPER AMM. 1999. Cytokines/chemokines cascades in inmunity to tuberculosis. Immunology today; 20:307-312. 108. ORME IM. 1988. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J. Immunol. 140, 3589–3593. 109. PAUL E, FINE M 2001. BCG: The Challenge Continues. Scand Journal Infect Disease; 33: 243-245. 110. PETROVSKY N, AGUILAR JC.2004. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 82(5):488-96. 111. PINTO R, SAUNDERS BM, CAMACHO LR, BRITTON WJ, GICQUEL B AND TRICCAS JA. 2004. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacilli Calmette-Guerin vaccine. Journal Infect Disease; 189(1): 105-2. Epub 2003 Dec 22. 112. PORCELLI A, MORITA CT, BRENNER MB. 1992. CD1b restricts the response of human CD4-8-T lymphocytes to microbial antigen. Nature. 360: 593-597. 113. PYM AS, BRODIN P, MAJLESS L, BROSCH R, DEMANGEL C, WILLIAMS A, GRIFFITHS KE, MARCHAL G, LECLERC C, COLE ST. 2003. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9:533-539. 114. QUESNIAUX V, FREMOND C, JACOBS M, PARIDA S, NICOLLE D, YEREMEEV V, BIHL F, ERARD F, BOTHA T, DRENNAN M. 2004. Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infection 6, 946-959. 115. RAJA A. 2004. Immunology of tuberculosis. Indian Journal Med Res; 120:213-23. 116. RAMBUKKANA A, DAS PK, KOLK AH, BURGGRAAF JD, KUIJPER S AND HARBOE M 1993. Identification of a novel 27 kDa protein from Mycobacterium tuberculosis culture fluid by monoclonal antibody specific for the Mycobacterium tuberculosis complex. Scand Journal Immunology; 37: 4714-478. 117. RAVIGLIONE M. 2006. XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis 10:1185-1187. 118. RINKE DE WIT TF, BEKELIE S, OSLAND A, WIELES B, JANSON AA AND THOLE JE 1993. The Mycobacterium leprae antigen 85 complex gene family: identification of the genes for the 85A, 85C and related and MPT51 proteins. Infection Immunology; 61: 3642-3647. 119. ROMANUS V. 1987 .Tuberculosis in Bacillus Calmette-Guerin-immunized and unimmunized children in Sweden: a ten-year evaluation following the cessation of general Bacillus Calmette-Guerin immunization of the newborn in 1975. Pediatr Infection Disease; 6:272-80. 120. RONNING RR, KLABUNDE T, BESRA GS, VISSA VD, BELISLE JT, SACCHETTINI JC. 2000. Crystal structure of the secreted form of antigen 85C reveal potential targets for mycobacterial drugs and vaccines. Nat Struct. Biol. 7:141-6. 121. ROSAT JP, GRANT EP, BECKMAN E. 1999. CD1-restricted microbial lipid antigen-speci9c recognition found in the CD8ab T cell pool. Journal Immunology: 162:366-373. 122. SABLE SB, GOYAL D, VERMA I, BEHERA D, KHULLER GK. 2007. Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. Europe Respir Journal ; 29(2):337-46. 123. SADEK M, SADA E, TOOSI Z, SCHWANDER S, RICH E 1998. Chemokines induced by infections of mononuclear phagocytes with Mycobacteria and present in lung Alveoli during active pulmonary tuberculosis, Am Respir Cell Mol Biol; 19:513-521. 124. SAMBANDAMURTHY VK, DERRICK SC, JALAPATHY KV, CHEN B, RUSSELL RG, MORRIS SL et al. 2005. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun, 73;1196–1203. 125. SANDER CR, PATHAN AA, BEVERIDGE NE, POULTON I, MINASSIAN A, ALDER N et al. 2009 Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med, 179:724–733. 126. SARTAIN MJ, SLAYDEN RA, SINGH KK, LAAL S and BELISLE JT. 2006. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Mol. Cell Proteomics 5:2102-2113 127. SCHLUGER NW 2001. Recent advances in our understanding of human host responses to tuberculosis. Respir Res; 2:157-163. 128. SCOTT-BROWNE JP, SHAFIANI S, TUCKER-HEARD G. 2007. Expasion and function of Foxp3-expressing T regulatory cells during tuberculosis. The Journal of Experimental Medicine. 204:2159-2169. 129. SEUBERT A, CALABRO S, SANTINI L, GALLI B, GENOVESE A, VALENTINI S, APREA S, COLAPRICO A, D'ORO U, GIULIANI MM, PALLAORO M, PIZZA M, O'HAGAN DT, WACK A, RAPPUOLI R, DE GREGORIO E. 2011. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A. 108(27): 11169-74. 130. SUTTERWALA FS, OGURA Y, FLAVELL RA. 2007. The inflammasome in pathogen recognition and inflammation.J Leukoc Biol. 82(2):259–64. 131. SHERMAN DR, VOSKUIL M, SCHNAPPINGER D, LIAO R, HARRELL MI, SCHOOLNIK GK. 2001. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc. Natl. Acad. Sci. USA 98, 7534−7539. 132. SILVA BD, DA SILVA EB, DO NASCIMENTO IP, DOS REIS MC, KIPNIS A, JUNQUEIRA-KIPNIS AP. 2009. MPT-51/CpG DNA vaccine protects mice against Mycobacterium tuberculosis. Vaccine, 16;27(33):4402-7. 133. SINGH KK, DONG Y, BELISLE JT, HARDER J, ARORA VK AND LAAL S. 2005. Antigens of Mycobacterium tuberculosis recognized by antibody during incipient, subclinical tuberculosis. Clin Diagn Lab Immunol; 12: 354-358. 134. SKEIKY YA, ALDERSON MR, OVENDALE PJ, GUDERIAN JA, BRANDT L, DILLON DC, CAMPOS-NETO A, LOBET Y, DALEMANS W, ORME IM, REED SG. 2004. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 172: 7618-28. 135. SMITH PG. 1987. Case-control studies of the efficacy of BCG against tuberculosis. In: International Union Against Tuberculosis, ed. Proceedings of the XXVIth IUAT World Conference on Tuberculosis and Respiratory Diseases. Singapore: Professional Postgraduate Services International, 73-9. 136. STENGER S, MODLIN RL. 1999. Cytotoxic T-Cell Responses to Intracellular Pathogens. Cytotoxic Cells: Basic Mechanisms and Medical Applications, edited by Sitkovsky MV, Henkart PA. Lippincott Williams & Wilkins, 269-279. 137. SUGAWARA, YAMADA H, UDAGAWA T, HUYGEN K . 2003. Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment. Tuberculosis (Edinb), 83, pp. 331–337. 138. TAKAYAMA K, WANG C, BESRA GS. 2005. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 18, 81–101. 139. TAN JS, CANADAY DH, BOOM WH, BALAJI KN, SCHWANDER SK, RICH EA 2000. Human alveolar T cell response to Mycobacterium tuberculosis antigens: role for CD4+ and CD8+ cytotoxic T Cells and relative resistance of alveolar macrophages to lysis. Journal Immunology; 159:290-297. 140. TCHILIAN EZ, DESEL C, FORBES EK, BANDERMANN S, SANDER CR, HILL AV, MCSHANE H, KAUFMANN SH. 2009 Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun. 77(2):622-31 141. TIDJANI O, AMEDOME A, TEN DAM HG. 1986. The protective effect of BCG vaccination of the newborn against childhood tuberculosis in an African community. Tubercle; 67:269-81. 142. TIGHE H, TAKABAYASHI K , SCHWARTZ D, MARSDEN R, BECK L, CORBEIL J, RICHMAN DD, EIDEN JJ, SPIEGELBERG HL, RAZ E. 2000. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol., 30,p. 1939. 143. UNDERHILL DM, OZINSKY A, SMITH KD, ADEREM A. 1999. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. PNAS v.96, n. 25, p.14459–14463. 144. VERNON A.2013. Treatment of Latent Tuberculosis Infection. Semin Respir Crit Care Med.; 34(1):67-86. 145. VERRECK FA, VERVENNE R, KONDOVA I, VAN KRALINGEN KW, REMARQUE EJ, BRASKAMP G et al. 2009. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One, 4, p. e5264. 146. VORDERMEIER HM, HUYGEN K, SINGH M, HEWINSON RG & XING Z. 2006 Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG. Infection Immunology. ; 74(2):1416-8. 147. WEINRICH OLSEN A, VAN PINXTEREN LA, MENG OKKELS L, BIRK RASMUSSEN P, ANDERSEN P. 2001. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and ESAT-6. Infect Immun, 69, pp. 2773–2778. 148. WHO Report 2012. Global Tuberculosis Reportl. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf, acessado em janeiro de 2013. 149. WILSON RA, MAUGHAN WN, KREMER L, BESRA GS AND FUTTERER K 2004. The structure of Mycobacterium tuberculosis MPT51 (FbpC1) defines a new family of non-catalytic alpha/beta hydrolases. Journal Mol Biology; 335: 519-530. 150. YOUNG D and DIE C. 2006. The development and impact of tuberculosis vaccines. Cell, 124, pp. 683–687 151. YUAN, Y., D. D. CRANE, R. M. SIMPSON, Y. Q. ZHU, M. J. HICKEY, D. R. SHERMAN, and C. E. BARRY III. 1998. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc. Natl. Acad. Sci. USA 95:9578-9583. 152. ZHANG M, GATELY MK, WANG E, GONG J, WOLF SF, LU S, MODLIN RL, BARNES PF 1994. Interleukin 12 at the site of disease in tuberculosis. Journal Clinical Investig; 93:1733-1739. |
Page generated in 0.0066 seconds